Clinical Trials Browser

Interventional × relatlimab × CNS × Clear all

NCT06325683 2026-03-18

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase 2 Recruiting

Glioblastoma

NCT05704933 2025-10-20

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Phase EARLY_PHASE1 Completed

CNSDermatologic

Brain Neoplasms, Melanoma